Proceeds Utilization - As of the announcement date, HKD 8.6 million of the net proceeds from the listing for organic development remains unused, with plans to utilize it by December 31, 2025[5]. - As of the announcement date, HKD 7.6 million of the net proceeds from the rights issue for medical beauty equipment registration remains unused, with plans to utilize it by March 31, 2026[6]. - The delay in utilizing the remaining proceeds is primarily due to the inability to identify suitable medical beauty institutions in Shanghai during the COVID-19 period from 2021 to 2024[5]. - The company aims to establish a medical beauty hospital in Shanghai to enhance customer confidence and brand influence[5]. - The company will continue to report the progress of the use of the proceeds to its shareholders and investors[6]. Share Options - The share options granted on August 23, 2021, had a closing price of HKD 0.485 and a fair value of HKD 0.080[7]. - The share options granted on August 29, 2022, had a closing price of HKD 0.167 and a fair value of HKD 0.076[7]. - The share options granted on January 26, 2024, had a closing price of HKD 0.112 and a fair value of HKD 0.079[7]. - The share options granted on February 23, 2024, had a closing price of HKD 0.122 and a fair value of HKD 0.082[7]. Supplementary Information - The supplementary information does not affect any other information contained in the 2024 annual report[8].
瑞丽医美(02135) - 2025 - 年度业绩